ArticleFrontiers in public health2025
Visual impairment and all-cause mortality: a real-world retrospective cohort study.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: VI (visual impairment) significantly impacts global public health, and there are few studies and inconsistent results on the impact of VI on mortality in Chinese adults. Our study aims to investigate the association between VI and the all-cause mortality risk in Chinese adults and to explore potential sex differences. Methods: This retrospective cohort (from July 17, 2010 to September 30, 2021) utilized data from the Yinzhou Health Information System, involving 182,468 individuals with valid visual acuity (VA) examination records. We assessed VI, defined as a presenting VA of the better eye worse than 0.5, using two variables: a binary variable (non-VI vs. VI) and a categorical variable (non-VI: VA ≥ 0.5; mild VI: 0.3 ≤ VA < 0.5; moderate VI: 0.1 ≤ VA < 0.3; severe VI: VA < 0.1). Cox proportional hazards multivariable regression models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the all-cause mortality risk. Subgroup analyses were also conducted based on sex and age. Results: During a median follow-up of 3.87 years, there were 2,632 death events, with 1,579 occurring in the non-visual impairment (VI) group and 1,053 in the VI group. Individuals with VI (VA < 0.5) had an increased all-cause mortality risk (HR, 1.15; 95% CI, 1.06-1.24), and this association persisted in old adults (HR, 1.15; 95% CI, 1.06-1.25). Old females with moderate or severe VI showed significantly higher all-cause mortality risks, with HRs of 1.32 (95% CI, 1.13-1.55) and 2.16 (95% CI, 1.35-3.46), respectively. Among old male participants, the increased all-cause mortality risk was only observed in those with moderate VI (HR, 1.42; 95% CI, 1.23-1.65). Conclusion: VI was associated with an increased all-cause mortality risk in Chinese old population. Sex differences were also observed in the associations between the VI level and the all-cause mortality risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.